Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether low concentration inhaled carbon monoxide is effective in treating idiopathic pulmonary fibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborators: Columbia University; National Heart, Lung, and Blood Institute (NHLBI); Tulane University; University of California, San Francisco; University of Chicago; University of Illinois at Chicago; University of Michigan; University of Washington
• Treatments: Carbon Monoxide

Criteria

Inclusion Criteria:

• Adults above the age of 18 and equal to or below the age of 85

• Diagnosis of IPF by biopsy or

• American Thoracic Society (ATS)/European Respiratory Society (ERS)/ Latin American Thoracic Association (ALAT) Guidelines (Am J Respir Crit Care Med Vol 183. pp 788-824,2011)

• Forced vital capacity (FVC) greater than or equal to 50% predicted, greater than or equal to one month off all medications prescribed for IPF

Exclusion Criteria:

• Evidence of active infection within the last month

• Significant obstructive respiratory defect

• Supplemental oxygen required to maintain an oxygen saturation over 88% at rest

• History of myocardial infarction within the last year, heart failure within the last 3 years or cardiac arrhythmia requiring drug therapy

• History of smoking within 4 weeks of screening

• Pregnancy or lactation

• Participation in another therapeutic clinical trial